Cannabidiol in vivo blunts β‐amyloid induced neuroinflammation by suppressing IL‐1β and iNOS expression
Open accessAbstract
BACKGROUND AND PURPOSE: Pharmacological inhibition of beta-amyloid (Abeta) induced reactive gliosis may represent a novel rationale to develop drugs able to blunt neuronal damage and slow the course of Alzheimer's disease (AD). Cannabidiol (CBD), the main non-psychotropic natural cannabinoid, exerts in vitro a combination of neuroprotective effects in different models of Abeta neurotoxicity. The present study, performed in a mouse model of AD-related neuroinflammation, was aimed at confirming in vivo the previously reported antiinflammatory properties of CBD. EXPERIMENTAL APPROACH: Mice were inoculated with human Abeta (1-42) peptide into the right dorsal hippocampus, and treated daily with vehicle or CBD (2.5 or 10 mg kg(-1), i.p.) for 7 days. mRNA for glial fibrillary acidic protein (GFAP) was assessed by in situ hybridization. Protein expression of GFAP, inducible nitric oxide synthase (iNOS) and IL-1beta was determined by immunofluorescence analysis. In addition, ELISA assay of IL-1beta level and the measurement of NO were performed in dissected and homogenized ipsilateral hippocampi, derived from vehicle and Abeta inoculated mice, in the absence or presence of CBD. KEY RESULTS: In contrast to vehicle, CBD dose-dependently and significantly inhibited GFAP mRNA and protein expression in Abeta injected animals. Moreover, under the same experimental conditions, CBD impaired iNOS and IL-1beta protein expression, and the related NO and IL-1beta release. CONCLUSION AND IMPLICATIONS: The results of the present study confirm in vivo anti-inflammatory actions of CBD, emphasizing the importance of this compound as a novel promising pharmacological tool capable of attenuating Abeta evoked neuroinflammatory responses.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CBD attenuates the depletion of tyrosine hydroxylase, GABA and dopamine levels by modulating the expression of inducible NO synthase and reducing the production of ROS-generating NADPH oxidases.
“and attenuates the depletion of tyrosine hydroxylase, GABA and dopamine levels by modulating the expression of the inducible isoform of NO synthase and reducing the production of ROS-generating NADPH oxidases (114–120).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [117]
In vivo, CBD attenuates Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression.
“In vivo, CBD has shown attenuation of Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression, as well as minimized reactive gliosis [187,190].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [190]
In vivo, CBD minimizes reactive gliosis.
“In vivo, CBD has shown attenuation of Aβ-induced neuroinflammatory responses by minimizing proinflammatory gene and mediator expression, as well as minimized reactive gliosis [187,190].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [190]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074 · see citing works
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656 · see citing works
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2× · see citing works
“While neurofibrillary tangles result from the deposition of hyperphosphorylated tau proteins (Lee et al., 1991), senile plaques represent more complex extracellular lesions composed of a core of b-amyloid (Ab) aggregates, surrounded by activated astrocytes and dystrophic neuritis (Itagaki et al.,…”
BackgroundRelationship of microglia and astrocytes to amyloid deposits of Alzheimer disease
Itagaki, S., McGeer, P. L., Akiyama, H., Zhu, S., & Selkoe, D. (1989) · Journal of Neuroimmunology · doi:10.1016/0165-5728(89)90115-x · Cited by 940 · see citing works
Ramírez, B. G., Blázquez, C., del Pulgar, T. G., Guzmán, M., & CEBALLOS, M. L. D. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4540-04.2005 · Cited by 785 · see citing works
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763 · see citing works
Griffin, W., Sheng, J. G., Royston, M., Gentleman, S., McKenzie, J., Graham, D. I., Roberts, G., & Mrak, R. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00136.x · Cited by 751 · see citing works
Amyloid diseases: Abnormal protein aggregation in neurodegeneration
Koo, E. H., Lansbury, P. T., & Kelly, J. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9989 · Cited by 686 · see citing works
Buxbaum, J. D., Oishi, M., Chen, H. I., Pinkas‐Kramarski, R., JAFFE, E. A., Gandy, S., & Greengard, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10075 · Cited by 558 · see citing works
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 511 · see citing works
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages
Rosa, M. D., Radomski, M. W., Carnuccio, R., & Moncada, S. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91583-e · Cited by 454 · see citing works
THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMERʼS DISEASE
Terry, R. D. (1963) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-196310000-00005 · Cited by 403 · cited 2× · see citing works
“Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder (Koo et al., 1999) whose specific hallmarks are neurofibrillary tangles (Terry, 1963) and senile plaques (Braak and Braak, 1997).”
BackgroundCosta, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395 · see citing works
Iuvone, T., Esposito, G., Esposito, R., Santamaria, R., Di Rosa, M., & Izzo, A. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2003.02327.x · Cited by 361 · see citing works
Self-citationCannabinoids and neuroinflammation
Walter, L. M., & Stella, N. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705667 · Cited by 334 · see citing works
Ueda, K., Shinohara, S., Yagami, T., Asakura, K., & Kawasaki, K. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68010265.x · Cited by 319 · see citing works
Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity
O'Callaghan, J. P., & Sriram, K. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.3.433 · Cited by 255 · see citing works
Esposito, G., Filippis, D. D., Carnuccio, R., Izzo, A. A., & Iuvone, T. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0025-1 · Cited by 252 · see citing works
Self-citationEsposito, G., De Filippis, D., Maiuri, M. C., De Stefano, D., Carnuccio, R., & Iuvone, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.01.047 · Cited by 225 · see citing works
Self-citationvan der Stelt, M., Mazzola, C., Esposito, G., Matias, I., Petrosino, S., Filippis, D. D., Micale, V., Steardo, L., Drago, F., Iuvone, T., et al. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6037-3 · Cited by 223 · see citing works
Self-citationNathan, C., Calingasan, N., Nezezon, J., Ding, A., Lucia, M. S., La Perle, K., Fuortes, M., Lin, M., Ehrt, S., Kwon, N. S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051529 · Cited by 214 · see citing works
Neuroprotective Antioxidants from Marijuana a
Hampson, A. J., GRIMALDI, M., Miljkovic-Lolic, M., Wink, D. A., Rosenthal, R., & Axelrod, J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06193.x · Cited by 203 · see citing works
Pro-inflammatory cytokines induce the transcription factors C/EBP? and C/EBP? in astrocytes
Cardinaux, J., Allaman, I., & Magistretti, P. J. (2000) · Glia · doi:10.1002/(sici)1098-1136(20000101)29:1 · Cited by 183 · see citing works
Das, S., & Potter, H. (1995) · Neuron · doi:10.1016/0896-6273(95)90300-3 · Cited by 166 · see citing works
Sheng, J. G., Mrak, R. E., Rovnaghi, C. R., Kozłowska, E., Eldik, L. J. V., & Griffin, W. S. T. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00037-1 · Cited by 156 · see citing works
Oxidative Stress, Perturbed Calcium Homeostasis, and Immune Dysfunction in Alzheimer's Disease
Mattson, M. P. (2002) · Journal of NeuroVirology · doi:10.1080/13550280290100978 · Cited by 142 · see citing works
Ranaivo, H. R., Craft, J. M., Hu, W., Guo, L., Wing, L. K., Eldik, L. J. V., & Watterson, D. M. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4652-05.2006 · Cited by 137 · see citing works
Caricasole, A., Copani, A., Caruso, A., Caraci, F., Iacovelli, L., Sortino, M. A., Terstappen, G. C., & Nicoletti, F. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00100-7 · Cited by 124 · see citing works
Interleukin-1 and the Immunogenetics of Alzheimer Disease
Mrak, R. E., & Griffin, W. S. T. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.471 · Cited by 119 · see citing works
Human amyloid β‐induced neuroinflammation is an early event in neurodegeneration
Craft, J. M., Watterson, D. M., & Eldik, L. J. V. (2005) · Glia · doi:10.1002/glia.20306 · Cited by 108 · see citing works
β-Amyloid Converts an Acute Phase Injury Response to Chronic Injury Responses
Cotman, C. W., Tenner, A. J., & Cummings, B. J. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00117-0 · Cited by 101 · see citing works
Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons.
Saez, T. E., Pehar, M., Vargas, M. R., Barbeito, L., & Maccioni, R. B. (2004) · PubMed · Cited by 67 · see citing works
Turner, R. S. (2006) · Seminars in Neurology · doi:10.1055/s-2006-951622 · Cited by 39 · see citing works
Green, K. N., & Peers, C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00907.x · Cited by 35 · see citing works
Jack fruit lectin binding pattern in benign and malignant lesions of the breast.
Remani, P., Augustine, J., Kk, V., et al. (1992) · PubMed · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Esposito, G., Scuderi, C., Valenza, M., Togna, G. I., Latina, V., De Filippis, D., Cipriano, M., Carratù, M. R., Iuvone, T., & Steardo, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028668 · Cited by 410 · see citing works
Self-citationPhytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · see citing works
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmx073 · Cited by 226 · see citing works
Sagredo, O., González, S., Aroyo, I., Pazos, M. R., Benito, C., Lastres‐Becker, I., Romero, J. P., Tolón, R. M., Mechoulam, R., Brouillet, E., et al. (2009) · Glia · doi:10.1002/glia.20838 · Cited by 201 · see citing works
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161 · see citing works
Self-citationDecreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
Gomes, F. V., Llorente, R., Del Bel, E. A., Viveros, M.-P., López-Gallardo, M., & Guimarães, F. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.01.015 · Cited by 147 · see citing works
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135 · see citing works
Janefjord, E., Mååg, J. L. V., Harvey, B. S., & Smid, S. D. (2014) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-013-9984-x · Cited by 118 · see citing works
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview
Libro, R., Giacoppo, S., Soundara Rajan, T., Bramanti, P., & Mazzon, E. (2016) · Molecules · doi:10.3390/molecules21040518 · Cited by 107 · see citing works
Fagherazzi, E. V., Garcia, V. A., Maurmann, N., Bervanger, T., Halmenschlager, L. H., Busato, S. B., Hallak, J. E., Zuardi, A. W., Crippa, J. A., & Schröder, N. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2449-3 · Cited by 87 · see citing works
Harvey, B. S., Ohlsson, K. S., Mååg, J. L. V., Musgrave, I. F., & Smid, S. D. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.015 · Cited by 82 · see citing works
Valvassori, S. S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Nisihara Chagas, M. H., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106925 · Cited by 80 · see citing works
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29 · see citing works
Natural Products from Plants and Algae for Treatment of Alzheimer’s Disease: A Review
Klose, J., Griehl, C., Roßner, S., & Schilling, S. (2022) · Biomolecules · doi:10.3390/biom12050694 · Cited by 23 · see citing works
- Authors
- Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L.
- Affiliations
- Sapienza University of Rome (IT)
- University of Naples Federico II (IT)
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-08
- Volume
- 151
- Issue
- 8
- Pages
- 1272-1279
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC2189818
- OpenAlex
- W1903625870
- Cited by
- 308
- References
- 36
- Citations by year
- 2026: 18 · 2025: 23 · 2024: 26 · 2023: 24 · 2022: 34 · 2021: 23 · 2020: 18 · 2019: 19 · 2018: 14 · 2017: 18 · 2016: 9 · 2015: 12 · 2014: 7 · 2013: 9 · 2012: 12
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cannabidiol, amyloid-beta, neuroinflammation, Alzheimer's disease, reactive gliosis, glial fibrillary acidic protein, inducible nitric oxide synthase, IL-1β, nitric oxide, hippocampus, anti-inflammatory activity, neuroprotection
- MeSH terms
- Animals, Cannabidiol, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme-Linked Immunosorbent Assay, Fluorescent Antibody Technique, Gene Expression Regulation, Glial Fibrillary Acidic Protein, Hippocampus, Inflammation, Mice, Inbred C57BL, Nitric Oxide, Peptide Fragments, RNA, Messenger, Amyloid beta-Peptides, Neuroprotective Agents, Neurotoxicity Syndromes, Mice, Nitric Oxide Synthase Type II, Interleukin-1beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
